Last reviewed · How we verify

PA — Competitive Intelligence Brief

PA (PA) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Visual cycle modulator / Retinoid analog. Area: Ophthalmology.

marketed Visual cycle modulator / Retinoid analog Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

PA (PA) — Fovea Pharmaceuticals SA. PA is a prodrug that is converted to its active form to modulate retinal function and treat vision disorders.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
PA TARGET PA Fovea Pharmaceuticals SA marketed Visual cycle modulator / Retinoid analog

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Visual cycle modulator / Retinoid analog class)

  1. Fovea Pharmaceuticals SA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PA — Competitive Intelligence Brief. https://druglandscape.com/ci/pa. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing